



Supplementary Material

Article Title: Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study

Authors: Kun Zhang, PhD; Christopher M. Jones, PharmD, DrPH; Wilson M. Compton, MD, MPE; Gery P. Guy, PhD, MPH; Mary E. Evans, MD; and Nora D. Volkow, MD

DOI Number: 10.4088/JCP.21m14001

List of Supplementary Material for the article

1. [Table 1](#) Buprenorphine Products Included in the Analysis as MOUD
2. [Table 2](#) Generic Drug Names of Antidepressants Included in the Analysis
3. [Table 3](#) Comorbid Conditions and Associated ICD-10 CM Codes
4. [Table 4](#) Generic Drug Names of Other Psychotropic Medications Included in the Analysis
5. [Table 5](#) Results of Cox Proportional Hazard Model for Sensitivity Analysis 1-3

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Material

Supplementary Table 1: Buprenorphine products included in the analysis as MOUD

| Non-injection Buprenorphine products | Included in analysis as MOUD | Suboxone dosage conversion factor |
|--------------------------------------|------------------------------|-----------------------------------|
| Buprenorphine Hydrochloride | Yes | 1 |
| Buprenorphine-Naloxone | Yes | 1 |
| BUNAVAIL | Yes | 1.905 |
| SUBLOCADE | Yes | N/A* |
| SUBOXONE | Yes | 1 |
| SUBUTEX | Yes | N/A* |
| ZUBSOLV | Yes | 1.4 |
| BELBUCA | No | N/A |
| BUTRANS | No | N/A |

* No prescription was identified in our data

Abbreviations: MOUD (medication for opioid use disorder)

Supplementary Table 2: Generic drug names of antidepressants included in the analysis

| Antidepressant categories | Generic drug names |
|--|---|
| Selective serotonin reuptake inhibitors (SSRIs) | citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline |
| Serotonin–norepinephrine reuptake inhibitors (SNRIs) | desvenlafaxine, duloxetine, levomilnacipran, venlafaxine |
| Tricyclic antidepressants (TCAs) | amitriptyline, amoxapine, clomipramine, desipramine, doxepin, Imipramine, maprotiline, nortriptyline, protriptyline, trimipramine |
| Other | bupropion, chlorprothixene, mirtazapine, nefazodone, nortriptyline, trazodone, vilazodone, vortioxetine |

Supplementary Table 3: Comorbid conditions and associated ICD-10 CM codes

| Comorbid conditions | ICD-10 CM Codes |
|---|--|
| <i>Substance use disorder</i> | |
| Alcohol use disorder | F10.1X, F10.2X, F10.9X |
| Cannabis use disorder | F12.1X, F12.2X, F12.9X |
| Cocaine use disorder | F14.1X, F14.2X, F14.9X |
| Sedative and hypnotic related disorder | F13.1X, F13.2X, F13.9X |
| Stimulant use disorder | F15.1X, F15.2X, F15.9X |
| Other psychoactive substance use disorder | F16.1X, F16.2X, F16.9X, F18.1X, F18.2X, F18.9X, F19.1X, F19.2X, F19.9X |
| <i>Psychiatric conditions</i> | |
| Anxiety | F40.0X, F40.1X, F40.2X, F40.8X, F40.9X, F41.0, F41.1, F41.3, F41.8, F41.9, F42.2, F42.3, F42.4, F42.8, F42.9 |

| | |
|--|---|
| Bipolar disorder | F30.1X, F30.2, F30.3, F30.4, F30.8, F30.9 |
| Major depression | F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.81, F32.89, F32.9 |
| Other mood disorder | F34.0, F34.1, F34.81, F34.89, F34.9, F39 |
| Attention deficit hyperactivity Disorder (ADHD) | F90.0, F90.1, F90.2, F90.8, F90.9 |
| Post-traumatic stress disorder (PTSD) | F43.10, F43.11, F43.12 |
| Schizophrenia | F20.0, F20.1, F20.2, F20.3, F20.5, F20.8X, F20.9, F25.0, F25.1, F25.8, F25.9, F29 |
| <i>Pain conditions</i> | |
| Back pain | M2578, M4000, M4003, M4004, M4005, M40202, M40203, M40204, M40205, M40209, M40292, M40293, M40294, M40295, M40299, M4030, M4035, M4036, M4037, M4100, M4102, M4103, M4104, M4105, M4106, M4107, M4108, M41112, M41113, M41114, M41115, M41116, M41117, M41119, M41122, M41123, M41124, M41125, M41126, M41127, M41129, M4120, M4122, M4123, M4124, M4125, M4126, M4127, M4130, M4134, M4135, M4180, M4182, M4183, M4184, M4185, M4186, M4187, M419, M4300, M4301, M4302, M4303, M4304, M4305, M4306, M4307, M4308, M4309, M4310, M4311, M4312, M4313, M4314, M4315, M4316, M4317, M4318, M4319, M4320, M4321, M4322, M4323, M4324, M4325, M4326, M4327, M4328, M438X9, M4640, M4644, M4645, M4646, M4647, M4648, M4649, M4710, M4714, M4715, M4716, M4720, M4724, M4725, M4726, M4727, M4728, M47814, M47815, M47816, M47817, M47818, M47819, M47894, M47895, M47896, M47897, M47898, M47899, M479, M4800, M4804, M4805, M4806, M48061, M48062, M4807, M4808, M4810, M4811, M4812, M4813, M4814, M4815, M4816, M4817, M4818, M4819, M4820, M4821, M4822, M4823, M4824, M4825, M4826, M4827, M4830, M4831, M4832, M4833, M4834, M4835, M4836, M4837, M4838, M489, M5104, M5105, M5106, M5114, M5115, M5116, M5117, M5124, M5125, M5126, M5127, M5134, M5135, M5136, M5137, M5146, M5147, M5184, M5185, M5186, M5187, M519, M532X7, M532X8, M533, M5380, M5384, M5385, M5386, M5387, M5388, M539, M5403, M5404, M5405, M5406, M5407, M5408, M5409, M5414, M5415, M5416, M5417, M5418, M5430, M5431, M5432, M5440, M5441, M5442, M545, M546, M5489, M549, M62830, M961, M962, M963, M965, M9922, M9923, M9924, M9925, M9926, M9927, M9928, M9929, M9932, M9933, M9934, M9935, M9936, M9937, M9938, M9939, M9942, M9943, M9944, M9945, M9946, M9947, M9948, M9949, M9952, M9953, M9954, M9955, M9956, M9957, M9958, M9959, M9962, M9963, M9964, M9965, M9966, M9967, M9968, M9969, M9972, M9973, M9974, M9975, M9976, M9977, M9978, M9979, M9983, M9984, M9902, M9904, Q762 |
| Neck pain (e.g., cervical spinal stenosis) | M47811, M47891, M4723, M4722, M4721, M47813, M47893, M47892, M47812, M47012, M4711, M47014, M47011, M4712, M47022, M47029, M47019, M47016, M47013, M47021, M4713, M47015, M50220, M5022, M5023, M5020, M50221, M50222, M50223, M5021, M5002, M5000, M5001, M50022, M50023, M50021, M50020, M5003, M5082, M5091, M5012, M50922, M50821, M5080, M5011, M50123, M50822, M50820, M50921, M5010, M4643, M5093, M50120, M50823, M5083, M50121, M5090, M4641, M50920, M50122, M4642, M5092, M50923, M5013, M5081, M9930, M9971, M9921, M9970, M4803, M9931, M9940, M9960, M9950, M4802, M9951, M4801, M9961, M9941, M9920, M542, M530, M531, M5413, M5411, M5412, M436, M5400, M5402, M5401, M5382, M5481, M5381, M5383 |
| Migraine | G43001, G43009, G43011, G43019, G43101, G43109, G43111, G43119, G43C0, G43B0, G43D0, G43A0, G43A1, G43C1, G43B1, G43D1, G43401, G43409, G43411, G43419, G43501, G43509, G43511, G43519, G43609, G43619, G43601, G43611, G43701, G43711, G43709, G43719, G43801, G43811, G43809, G43819, G43901, G43911, G43909, G43919, G43821, G43829, G43831, G43839 |
| Fibromyalgia | M797 |
| Osteoarthritis/joint cartilage | M129, M131X, M138X, M15X, M16X, M17X, M18X, M19X, M2210, M2211, M2212, M222X, M223X, M224X, M228X, M2290, M2291, M2292, M23X, M241X |
| Inflammatory joint disorder (e.g., rheumatoid arthritis, ankylosing spondylitis) | M05X, M06X, M08X, M120X, M255X, M353, M45X, M460X, M461, M465X, M468X, M469X, M488X, M498X, M790 |

| | |
|--|---|
| Periarticular/soft tissue Disorders (e.g., peripheral enthesopathies, synovitis, bursitis) | M2570, M25711, M25712, M25719, M25721, M25722, M25729, M25731, M25732, M25739, M25741, M25742, M25749, M25751, M25752, M25759, M25761, M25762, M25769, M2577X, M701X, M702X, M704X, M705X, M706X, M707X, M7500, M7501, M7502, M751X, M7520, M7521, M7522, M7530, M7531, M7532, M7540, M7541, M7542, M7550, M7551, M7552, M7580, M7581, M7582, M7590, M7591, M7592, M76X, M77X, M2161X, M2162X, M65X, M66X, M67X, M700X, M7030, M7031, M7032, M71X |
|--|---|

Note: a code ending with X means that the code includes all digits at X's position.

Supplementary Table 4: Generic drug names of other psychotropic medications included in the analysis

| Therapeutic classes of other psychotropic medications | Generic drug names |
|---|--|
| Benzodiazepines | alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, oxazepam, prazepam, quazepam, temazepam, triazolam |
| Stimulants | amphetamine, dextmethylphenidate, dextroamphetamine, lisdexamphetamine, methylphenidate |
| Opioid analgesics | buprenorphine (only Butrans and Belbuca), butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, pentazocine, tapentadol, tramadol |
| Other psychotropics | aripiprazole, buspirone, carbamazepine, chlorpromazine, clozapine, divalproex, droperidol, felbamate, fluphenazine, gabapentin, haloperidol, lamotrigine, levetiracetam, lithium, loxapine, lurasidone, olanzapine, oxcarbazepine, paliperidone, perphenazine, pregabalin, prochlorperazine, promazine, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, valproic, ziprasidone |

Supplementary Table 5: Results of Cox proportional hazard model for sensitivity analysis 1 - 3

| <i>Parameter</i> | <i>Level</i> | Analysis 1 (only patients with baseline OUD diagnosis), N=7,799 | | | Analysis 2 (using 30-day gap to define discontinuation), N=11,619 | | | Analysis 3 (patients with no antidepressants and those received antidepressants < 15 days), N=6,933 | | |
|--|---|---|----------------------|-------|---|----------------------|-------|---|----------------------|-------|
| | | Hazard Ratio | [95% Conf. Interval] | | Hazard Ratio | [95% Conf. Interval] | | Hazard Ratio | [95% Conf. Interval] | |
| | Antidepressants only in 6 months prior to buprenorphine treatment | 1.318 | 1.170 | 1.485 | 1.405 | 1.284 | 1.537 | 1.345 | 1.229 | 1.472 |
| Antidepressant status (ref=no antidepressants at all) | Antidepressants during treatment: | | | | | | | | | |
| | Antidepressants only during treatment | 0.702 | 0.637 | 0.774 | 0.734 | 0.683 | 0.789 | 3.014 | 2.100 | 4.327 |
| | Antidepressants in 6 months prior to and during treatment | 0.540 | 0.489 | 0.610 | 0.509 | 0.464 | 0.557 | 2.864 | 2.410 | 3.404 |
| Age group (ref=18-34) | 35-44 | 0.649 | 0.592 | 0.710 | 0.669 | 0.627 | 0.714 | 0.735 | 0.677 | 0.797 |
| | 45-54 | 0.786 | 0.709 | 0.872 | 0.805 | 0.748 | 0.867 | 0.880 | 0.799 | 0.969 |
| | 55-64 | 0.736 | 0.649 | 0.835 | 0.853 | 0.782 | 0.930 | 0.974 | 0.870 | 1.091 |
| Daily dose of buprenorphine (ref=2-8mg) | 9-12mg | 0.806 | 0.729 | 0.892 | 0.781 | 0.724 | 0.844 | 0.761 | 0.688 | 0.841 |
| | 13-16mg | 0.845 | 0.778 | 0.918 | 0.803 | 0.755 | 0.854 | 0.806 | 0.747 | 0.871 |
| | 17-24mg | 0.713 | 0.644 | 0.790 | 0.666 | 0.619 | 0.717 | 0.674 | 0.614 | 0.739 |
| | >24mg | 1.012 | 0.804 | 1.273 | 0.912 | 0.776 | 1.071 | 0.966 | 0.792 | 1.177 |
| Gender (ref = Female) | Male | 0.952 | 0.888 | 1.021 | 0.911 | 0.865 | 0.959 | 0.907 | 0.847 | 0.970 |
| Use of benzodiazepine (ref=no benzodiazepines at all) | Benzodiazepines only in 6 months prior to treatment | 1.197 | 1.069 | 1.341 | 1.312 | 1.204 | 1.430 | 1.271 | 1.131 | 1.427 |
| | Benzodiazepines only during treatment | 0.983 | 0.868 | 1.112 | 0.942 | 0.859 | 1.033 | 0.932 | 0.820 | 1.060 |
| | Benzodiazepines in 6 months prior to and during treatment | 1.176 | 1.066 | 1.298 | 1.168 | 1.087 | 1.255 | 1.224 | 1.103 | 1.357 |
| Use of opioid analgesics (ref=no opioid analgesics at all) | Opioid analgesics only in 6 months prior to treatment | 1.016 | 0.932 | 1.107 | 1.000 | 0.938 | 1.067 | 1.065 | 0.982 | 1.155 |
| | Opioid analgesics only during treatment | 0.522 | 0.439 | 0.622 | 0.511 | 0.447 | 0.583 | 0.430 | 0.355 | 0.522 |
| | Opioid analgesics in 6 months prior to and during treatment | 0.859 | 0.761 | 0.970 | 0.951 | 0.874 | 1.034 | 1.042 | 0.930 | 1.168 |
| Use of stimulant (ref=no stimulants at all) | Stimulants only in 6 months prior to treatment | 1.208 | 0.991 | 1.473 | 1.357 | 1.166 | 1.581 | 1.312 | 1.076 | 1.600 |

| | | | | | | | | | | |
|---|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | Stimulants only during treatment | 0.518 | 0.428 | 0.627 | 0.530 | 0.459 | 0.612 | 0.454 | 0.360 | 0.574 |
| | Stimulants in 6 months prior to and during treatment | 0.878 | 0.747 | 1.031 | 0.887 | 0.792 | 0.994 | 0.826 | 0.700 | 0.974 |
| Use of other psychotropic prescriptions (OPP) (ref=no OPP at all) | OPP only in 6 months prior to treatment | 1.257 | 1.115 | 1.417 | 1.298 | 1.184 | 1.423 | 1.248 | 1.118 | 1.393 |
| | OPP only during treatment | 0.938 | 0.847 | 1.040 | 0.949 | 0.879 | 1.025 | 0.957 | 0.857 | 1.069 |
| | OPP in 6 months prior to and during treatment | 0.951 | 0.864 | 1.047 | 1.005 | 0.935 | 1.081 | 1.035 | 0.932 | 1.150 |
| Alcohol use disorder | Diagnosis present at baseline | 1.042 | 0.931 | 1.167 | 1.026 | 0.926 | 1.137 | 1.043 | 0.901 | 1.207 |
| Cannabis use disorder | Diagnosis present at baseline | 1.273 | 1.133 | 1.431 | 1.266 | 1.134 | 1.412 | 1.161 | 0.991 | 1.361 |
| Sedative and hypnotic related disorder | Diagnosis present at baseline | 1.009 | 0.891 | 1.142 | 0.997 | 0.888 | 1.119 | 1.029 | 0.878 | 1.206 |
| Cocaine use disorder | Diagnosis present at baseline | 1.270 | 1.100 | 1.468 | 1.230 | 1.069 | 1.416 | 1.015 | 0.830 | 1.241 |
| Stimulant use disorder | Diagnosis present at baseline | 1.373 | 1.194 | 1.579 | 1.311 | 1.148 | 1.497 | 1.292 | 1.060 | 1.575 |
| Other psychoactive substance use disorder | Diagnosis present at baseline | 1.090 | 0.991 | 1.200 | 1.048 | 0.965 | 1.139 | 1.030 | 0.922 | 1.151 |
| Anxiety | Diagnosis present at baseline | 0.971 | 0.896 | 1.053 | 0.939 | 0.880 | 1.002 | 0.932 | 0.851 | 1.019 |
| Bipolar disorder | Diagnosis present at baseline | 1.177 | 1.027 | 1.349 | 1.112 | 0.991 | 1.248 | 1.105 | 0.923 | 1.324 |
| Major depression | Diagnosis present at baseline | 1.128 | 1.036 | 1.227 | 1.077 | 1.005 | 1.153 | 1.177 | 1.061 | 1.306 |
| ADHD | Diagnosis present at baseline | 1.045 | 0.898 | 1.216 | 1.064 | 0.943 | 1.200 | 1.019 | 0.853 | 1.218 |
| Other mood disorder | Diagnosis present at baseline | 0.944 | 0.793 | 1.125 | 0.939 | 0.812 | 1.085 | 1.085 | 0.832 | 1.416 |
| PTSD | Diagnosis present at baseline | 1.074 | 0.887 | 1.301 | 1.065 | 0.913 | 1.243 | 1.054 | 0.821 | 1.352 |
| Schizophrenia | Diagnosis present at baseline | 0.925 | 0.692 | 1.237 | 1.038 | 0.805 | 1.339 | 1.190 | 0.807 | 1.757 |
| Back pain | Diagnosis present at baseline | 1.020 | 0.936 | 1.112 | 1.034 | 0.968 | 1.104 | 0.990 | 0.907 | 1.082 |
| Neck pain | Diagnosis present at baseline | 1.049 | 0.935 | 1.176 | 1.079 | 0.991 | 1.174 | 1.090 | 0.964 | 1.232 |
| Migraine | Diagnosis present at baseline | 0.984 | 0.821 | 1.179 | 1.069 | 0.944 | 1.210 | 1.078 | 0.916 | 1.270 |
| Fibromyalgia | Diagnosis present at baseline | 1.071 | 0.851 | 1.348 | 1.151 | 0.978 | 1.355 | 1.211 | 0.939 | 1.562 |
| Osteoarthritis/joint cartilage | Diagnosis present at baseline | 0.932 | 0.806 | 1.079 | 0.987 | 0.887 | 1.097 | 0.971 | 0.830 | 1.135 |
| Inflammatory joint disorder | Diagnosis present at baseline | 0.977 | 0.876 | 1.090 | 1.002 | 0.925 | 1.085 | 1.052 | 0.944 | 1.172 |
| Periarticular/soft tissue disorders | Diagnosis present at baseline | 1.321 | 1.120 | 1.559 | 1.294 | 1.145 | 1.461 | 1.214 | 1.036 | 1.422 |

Abbreviations: ADHD (Attention deficit hyperactivity disorder), PTSD (Post-traumatic stress disorder)